New data presented on us of sebeltralstat to relieve breakthrough attacks in HAE patients on long-term prophylaxis
Effective on-demand (OD) treatment for HAE attacks remains extremely important among patients receiving long-term prophylaxis (LTP), according to new data presented at the recent 2025 European Academy of Allergy and Clinical Immunology (EAACI) Congress. The pharmaceutical company KalVista said the data showed that:
- Less than half (44%) of HAE patients using LTP were adherent based on refill data over 12 months
- In an analysis of a trial, involving 35 participants receiving berotralstat, lanadelumab, or C1 inhibitor (C1-INH), 382 attacks were treated with sebetralstat
One of the clinical trialists, Dr Marc Riedl MD, Professor of Medicine and Clinical Director of the US Hereditary Angioedema Association Center at the University of California, San Diego, commented: “Even with advancements in HAE long-term prophylactic treatments, attacks still occur, highlighting the critical need for easily administered, fast-acting, effective on-demand options,” said “These data show the promise of sebetralstat as an effective oral on-demand option that can complement all major long-term prophylaxis treatments, including those acting through plasma kallikrein inhibition, like lanadelumab and berotralstat.”
Paul Audhya, MD MBA, Chief Medical Officer of KalVista, said: “These data reinforce what we hear from patients and clinicians on an ongoing basis; long-term prophylaxis plays an essential role in HAE management, but it’s not the full story. Attacks still occur, and adherence remains a real-world challenge. Sebetralstat is designed to meet this need: a rapid, reliable oral treatment that empowers patients to act the moment symptoms begin, regardless of their background therapy.”
(Source: KalVista)